FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2144802145> ?p ?o ?g. }

• W2144802145 endingPage "1625" @default.
• W2144802145 startingPage "1618" @default.
• W2144802145 abstract "We investigated the impact of patient and disease characteristics, including cytogenetics, previous therapy, and depth of response, on the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) for patients with myelodysplastic syndrome (MDS). We analyzed 256 MDS patients who underwent transplantation from a matched related (n = 133) or matched unrelated (n = 123) donor after 2001. Of the 256, 78 (30.5%) did not receive cytoreductive therapy before HSCT; 40 (15.6%) received chemotherapy, 122 (47.7%) received hypomethylating agents (HMA), and 16 (6.2%) received both (chemo+HMA). Disease status at HSCT defined by International Working Criteria was complete remission in 46 (18%) patients. There were significant differences between therapy groups: there were more therapy-related MDS and higher use of matched related donor in the untreated group. The chemotherapy group had higher serum ferritin levels at HSCT. Patients were older and had more high-risk disease by revised International Prognostic Scoring in the HMA group. Despite those differences, transplantation outcomes were similar in patients who were untreated and who received cytoreductive therapy before HSCT. Three-year event-free survival (EFS) was 44.2%, 30.6%, 34.2%, and 32.8% for untreated, chemotherapy, HMA, and chemo+HMA groups, respectively (P = .50). Multivariate analyses revealed that older age (hazard ratio [HR], 1.3; P = .001); high-risk histologic subtypes, including refractory anemia with excess blasts (HR, 1.5; P = .05) and chronic myelomonocytic leukemia (HR, 2.1; P = .03), high-risk cytogenetics with monosomal karyotype (MK) (HR, 4.0; P < .0001) and high serum ferritin level at HSCT (HR, 1.8; P = .002) were poor prognostic factors for EFS. Bone marrow blast count 5% or higher at HSCT (HR, 1.6; P = .01) and MK (HR, 4.2; P < .0001) were the only prognostic factors for increased relapse incidence after HSCT. Patients with MK represented a poor prognostic group, with 3-year EFS of 11.4% and relapse incidence of 60.9%. In this analysis, various therapy approaches before HSCT did not lead to different transplantation outcomes. Cytogenetics defined by MK was able to identify a very poor prognostic groups that innovative transplantation approaches to improve outcomes are urgently needed." @default.
• W2144802145 created "2016-06-24" @default.
• W2144802145 creator A5004417292 @default.
• W2144802145 creator A5034104852 @default.
• W2144802145 creator A5034264716 @default.
• W2144802145 creator A5048913229 @default.
• W2144802145 creator A5049385583 @default.
• W2144802145 creator A5055885795 @default.
• W2144802145 creator A5057598469 @default.
• W2144802145 creator A5060818696 @default.
• W2144802145 creator A5066894053 @default.
• W2144802145 creator A5067807357 @default.
• W2144802145 creator A5069460930 @default.
• W2144802145 creator A5075342012 @default.
• W2144802145 creator A5085076031 @default.
• W2144802145 creator A5091083304 @default.
• W2144802145 date "2014-10-01" @default.
• W2144802145 modified "2023-10-11" @default.
• W2144802145 title "Cytogenetics, Donor Type, and Use of Hypomethylating Agents in Myelodysplastic Syndrome with Allogeneic Stem Cell Transplantation" @default.
• W2144802145 cites W1796660362 @default.
• W2144802145 cites W1963676570 @default.
• W2144802145 cites W1970409181 @default.
• W2144802145 cites W1970925222 @default.
• W2144802145 cites W1974632374 @default.
• W2144802145 cites W1990214407 @default.
• W2144802145 cites W2005499564 @default.
• W2144802145 cites W2022978986 @default.
• W2144802145 cites W2028795322 @default.
• W2144802145 cites W2035592289 @default.
• W2144802145 cites W2038581469 @default.
• W2144802145 cites W2039474819 @default.
• W2144802145 cites W2048706755 @default.
• W2144802145 cites W2058219901 @default.
• W2144802145 cites W2078790776 @default.
• W2144802145 cites W2096638244 @default.
• W2144802145 cites W2098454439 @default.
• W2144802145 cites W2104319503 @default.
• W2144802145 cites W2117446917 @default.
• W2144802145 cites W2129510594 @default.
• W2144802145 cites W2134214323 @default.
• W2144802145 cites W2162154486 @default.
• W2144802145 cites W2167765664 @default.
• W2144802145 cites W2171077812 @default.
• W2144802145 cites W2271039096 @default.
• W2144802145 cites W2326726820 @default.
• W2144802145 cites W4242962945 @default.
• W2144802145 doi "https://doi.org/10.1016/j.bbmt.2014.06.022" @default.
• W2144802145 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6201698" @default.
• W2144802145 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24953017" @default.
• W2144802145 hasPublicationYear "2014" @default.
• W2144802145 type Work @default.
• W2144802145 sameAs 2144802145 @default.
• W2144802145 citedByCount "42" @default.
• W2144802145 countsByYear W21448021452014 @default.
• W2144802145 countsByYear W21448021452015 @default.
• W2144802145 countsByYear W21448021452016 @default.
• W2144802145 countsByYear W21448021452017 @default.
• W2144802145 countsByYear W21448021452018 @default.
• W2144802145 countsByYear W21448021452019 @default.
• W2144802145 countsByYear W21448021452020 @default.
• W2144802145 countsByYear W21448021452021 @default.
• W2144802145 countsByYear W21448021452022 @default.
• W2144802145 countsByYear W21448021452023 @default.
• W2144802145 crossrefType "journal-article" @default.
• W2144802145 hasAuthorship W2144802145A5004417292 @default.
• W2144802145 hasAuthorship W2144802145A5034104852 @default.
• W2144802145 hasAuthorship W2144802145A5034264716 @default.
• W2144802145 hasAuthorship W2144802145A5048913229 @default.
• W2144802145 hasAuthorship W2144802145A5049385583 @default.
• W2144802145 hasAuthorship W2144802145A5055885795 @default.
• W2144802145 hasAuthorship W2144802145A5057598469 @default.
• W2144802145 hasAuthorship W2144802145A5060818696 @default.
• W2144802145 hasAuthorship W2144802145A5066894053 @default.
• W2144802145 hasAuthorship W2144802145A5067807357 @default.
• W2144802145 hasAuthorship W2144802145A5069460930 @default.
• W2144802145 hasAuthorship W2144802145A5075342012 @default.
• W2144802145 hasAuthorship W2144802145A5085076031 @default.
• W2144802145 hasAuthorship W2144802145A5091083304 @default.
• W2144802145 hasBestOaLocation W21448021451 @default.
• W2144802145 hasConcept C104317684 @default.
• W2144802145 hasConcept C126322002 @default.
• W2144802145 hasConcept C143998085 @default.
• W2144802145 hasConcept C174475383 @default.
• W2144802145 hasConcept C185592680 @default.
• W2144802145 hasConcept C207103383 @default.
• W2144802145 hasConcept C2776694085 @default.
• W2144802145 hasConcept C2777408962 @default.
• W2144802145 hasConcept C2777928532 @default.
• W2144802145 hasConcept C2780007613 @default.
• W2144802145 hasConcept C2780240888 @default.
• W2144802145 hasConcept C2780817109 @default.
• W2144802145 hasConcept C2911091166 @default.
• W2144802145 hasConcept C30481170 @default.
• W2144802145 hasConcept C44249647 @default.
• W2144802145 hasConcept C55493867 @default.
• W2144802145 hasConcept C71924100 @default.
• W2144802145 hasConcept C90924648 @default.
• W2144802145 hasConceptScore W2144802145C104317684 @default.

• next